China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021 has recently announced the addition of a market study “ China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021 , is a comparative analysis of the global market.

The in–vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high–end products and an increase in the number of private hospitals and independent testing laboratories. However, low reimbursement rate, absence of quality products by the local companies, population factors and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth of this market.

Long–term Outlook: The China In Vitro Diagnostics Market is expected to reach more than US$ 10 Billion by 2021 with strong double digit growth rate from 2016 to 2021.

China IVD Market: Segment wise Outlook

Immunoassay has emerged as a significant rapidly growing market segment in China IVD market. Immunoassay test controls nearly XX% market share by the year 2021. Other segments such as Clinical Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near future. Growing demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will usher the China IVD market.

China IVD Market: Companies wise Outlook

Roche is the leading company with more than XX% market share in the China IVD market and is expected to hold its strong position in the market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi–auto and automatic biochemistry analyzers to low and mid–end market users.

Download The sample Copy Of This Report:

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market, market segments, company wise sales analysis, regulation, major distributors and laboratories of IVD and outlook of the Chinese IVD companies.

This report titled “China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021” has been analyzed from 10 viewpoints:

Market and Forecast (2010 – 2021)

Segment Wise Market and Forecast (2010 – 2021)

Company Wise IVD Sales and Forecast (2010 – 2021)

Regulation and its Latest Development

Future Prospects in Attractive In Vitro Diagnostics Segments

Regional Trends and Opportunities

Main Participants/Contributors

Major IVD Product Companies Outlook

Major Private Clinical Labs and Diagnostic Services Companies Outlook

Market Growth Drivers and Challenges

The following segments of the China In Vitro Diagnostics market are detailed with size and six year forecast.

Clinical Chemistry


Molecular Testing

Self–Monitoring of Blood Glucose (SMBG)

Point of Care Testing (POCT)




The following companies of the China In Vitro Diagnostics market are detailed with size and six year forecast

Roche Diagnostics

Abbott Laboratories

Mindray Medical International Limited

Sysmex Corporation

Shanghai Kehua Bio–Engineering Co. Ltd.

Other Companies

The following Chinese companies of the China In Vitro Diagnostics market are detailed with company overview and its product portfolio

Mindray Medical International Limited

Shanghai Fosun Pharmaceutical Group

Mingyuan Medicare

Da An Gene Co. Ltd.

Shanghai Kehua Bio–Engineering Co. Ltd.

Zhejiang D.a. Diagnostics Technology Co., Ltd

ADICON Clinical Laboratories

Guangzhou Kingmed Diagnostics Center Co. Ltd.

Kindstar Global

BGI – Shenzhen

OriGene Technologies

Key Highlights

In March 2015, the government announced plans to build a new capital city to the east of Cairo near the Red Sea, in an aim to promote economic growth. The project was suspended temporarily following lack of consensus on the projects tenure and cost. However, the government re-announced the commencement of the project in February 2016. The new capital city will include 1.1 million housing units, 663 healthcare facilities, 700 kindergartens, 40,000 hotel rooms, 1,250 religious buildings, and retail malls on a 1.8 million m2 area, theme parks and an airport.

Egypts strategic geographical location and availability of cheap and competitive workforce is increasing the pace of foreign direct investment (FDI) in the country. According to the United Nations Conference on Trade and Development (UNCTAD)s 2015 World Investment Report, the oil sector represented the highest recipient of FDI with a share of 71.7% during 20142015, followed by the construction and manufacturing sectors with 2.2% and 2.0% shares respectively.

In a bid to minimize traffic congestion in Cairo, the Egyptian Ministry of Transport announced plans to construct Cairo Metro Line 6. Accordingly, the Ministry of Transport signed a memorandum of understanding (MOU) with the China Railway Construction Corporation worth EGP26.1 billion (US$3.5 billion) in December 2015. The 30km-long metro line project will connect northern Al-Khosos and the southern suburb of Maadi.

In 2015, the government signed a MoU with Rosatom State Atomic Energy Corporation of Russia to construct a nuclear power station in El Dabaa region. With a total investment of EGP186.2 billion (US$25.0 billion), the plant will be developed with a capacity to generate 4,800MW of electricity. The plant is expected to be completed in 2022.

The government is accelerating the pace of investment under the public-private partnership (PPP) model. In February 2016, the Egyptian Ministry of Housing signed four PPP contracts with major real estate companies which include Mountain View-Sisban Holding alliance, Arabia Group and Palm Hills. The total value of these PPP projects is EGP200.0 billion (US$26.8 billion) and includes developments such as the Mountain View iCity residential project in the New Cairo city which will cover a 2.1km2 area with 18,000 housing units, and a resort.

Table of Contents

1. Executive Summary

2. China In Vitro Diagnostics Market & Forecast (2010 – 2021)

3. China In Vitro Diagnostics Market Share & Forecast (2010 – 2021)

3.1 China In Vitro Diagnostics Market Share Outlook

3.2 China In Vitro Diagnostics Companies Share Outlook

4. China In Vitro Diagnostics Market – Segment Analysis (2010 – 2021)

4.1 China Clinical Chemistry Market & Forecast

4.2 China Immunoassay Market & Forecast

4.3 China Molecular Testing Market & Forecast

4.4 China Self–Monitoring of Blood Glucose (SMBG) Market & Forecast

4.5 China Point of Care Testing (POCT) Market & Forecast

4.6 China Hematology Market & Forecast

4.7 China Coagulation Market & Forecast

4.8 China Microbiology Market & Forecast

5. China In Vitro Diagnostics Market – Company Wise Sales Analysis (2010 – 2021)

5.1 Roche Diagnostics – China IVD Sales & Forecast

5.2 Abbott Laboratories – China IVD Sales & Forecast

5.3 Mindray Medical International Limited – China IVD Sales & Forecast

5.4 Sysmex Corporation – China IVD Sales & Forecast

5.5 Shanghai Kehua Bio–Engineering Co. Ltd. – China IVD Sales & Forecast

5.6 Other Companies – China IVD Sales & Forecast

6. China IVD – Regulation & its Latest Development

7. China IVD – Future Prospects in Attractive In Vitro Diagnostics Segments

8. China IVD – Regional Trends & Opportunities

9. China IVD – Main Participants/Contributors

9.1 China IVD Market – Main Distributors

9.2 China IVD Market – Major Laboratories

9.3 China IVD Market – Major Foreign & Regional Companies

10. China – Major IVD Product Companies Outlook

10.1 Mindray Medical International Limited

10.2 Shanghai Fosun Pharmaceutical Group

10.3 Mingyuan Medicare

10.4 Da An Gene Co. Ltd

10.5 Shanghai Kehua Bio–Engineering Co. Ltd

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at


Mr. Nachiket

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948



Follow us on LinkedIn: